168 results on '"Lubel, John S"'
Search Results
2. Management of hepatitis D in general practice
3. Hepatocellular carcinoma surveillance based on the Australian Consensus Guidelines: a health economic modelling study
4. High end‐of‐treatment hepatitis B core‐related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy.
5. Late-Life Metabolic Dysfunction-Associated Steatotic Liver Disease and its Association With Physical Disability and Dementia
6. Evaluation of a 12-week targeted vitamin D supplementation regimen in patients with active inflammatory bowel disease
7. Reply to Abenavoli et al. Comment on “Clayton-Chubb et al. Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives. Nutrients 2023, 15, 687”
8. Metabolic dysfunction‐associated steatotic liver disease in older adults is associated with frailty and social disadvantage.
9. A systematic review on the complications and management of hepatic adenomas: a call for a new approach
10. Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives
11. Additional file 1 of Hepatocellular carcinoma surveillance based on the Australian Consensus Guidelines: a health economic modelling study
12. What do we know about the renin angiotensin system and inflammatory bowel disease?
13. Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling Pathways
14. Outcomes of microwave versus radiofrequency ablation for hepatocellular carcinoma: A systematic review and meta-analysis
15. Stopping nucleot(s)ide analogues in non‐cirrhotic HBeAg‐negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels
16. Australian consensus recommendations for the management of hepatitis B
17. Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling Pathways.
18. Clinical outcomes of patients with two small hepatocellular carcinomas
19. Australian recommendations for the management of hepatocellular carcinoma
20. Prevalence of non‐alcoholic fatty liver disease in regional Victoria: a prospective population‐based study
21. Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis
22. Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2
23. Current issues in the prevalence, diagnosis and management of hepatocellular carcinoma in Australia
24. Lessons From COVID-19, ACE2, and Intestinal Inflammation: Could a Virus Trigger Chronic Intestinal Inflammation?
25. Australian recommendations for the management of hepatocellular carcinoma: a consensus statement
26. Entering the new era of direct acting antivirals for chronic hepatitis C - where have we come from? Current all-genotype results of the Eastern Health Hepatology Unit
27. Education does not improve hepatitis B screening uptake in those receiving cytotoxic chemotherapy - time for alternative strategies
28. Circulating components of the alternative reninangiotensin system are upregulated in patients with inflammatory bowel disease
29. Total, free and bioavailable vitamin D inversely correlate with faecal calprotectin in patients with inflammatory bowel disease (IBD)
30. Ultrasonography evaluation of the fibrosis stage in chronic liver disease - correlation with liver stiffness measurement from fibroscan
31. ASMA predicts for pre-treatment liver biopsy and delays normalisation of ALT during the first 12 weeks of therapy with pegylated interferon and ribavirin but has no impact on SVR
32. Considerable variation in approach to chemoembolisation by interventional radiologists treating hepatocellular carcinoma is standardised treatment feasible?
33. Conventional transarterial chemoembolization versus doxorubicin bead transarterial chemoembolization for the treatment of hepatocellular carcinoma, a retrospective cohort study
34. Gastrointestinal ACE2, COVID-19 and IBD: Opportunity in the Face of Tragedy?
35. Letter: ACE2, IBD and COVID‐19—why IBD patients may be at reduced risk of COVID‐19
36. Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors
37. Epidemiology and outcomes of marked elevations of alanine aminotransferase >1000 IU/L in an Australian cohort
38. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: Diagnosis and management
39. Liver disease and the renin–angiotensin system: Recent discoveries and clinical implications
40. Supplementary_Material – Supplemental material for The intestinal vitamin D receptor in inflammatory bowel disease: inverse correlation with inflammation but no relationship with circulating vitamin D status
41. The intestinal vitamin D receptor in inflammatory bowel disease: inverse correlation with inflammation but no relationship with circulating vitamin D status
42. Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population‐based study
43. Accidental paracetamol poisoning
44. Abdominal Pain Following Drug-Eluting Bead Transarterial Chemoembolisation
45. Upregulation of circulating components of the alternative renin-angiotensin system in inflammatory bowel disease: A pilot study
46. Association of Circulating Vitamin D Concentrations with Intestinal but Not Systemic Inflammation in Inflammatory Bowel Disease
47. Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis
48. Gallbladder perforation following transarterial chemoembolisation; a rare but serious complication
49. Hepatitis Without Hepatitis?
50. Angiotensin-(1–7), an alternative metabolite of the renin–angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.